Loading...
Loading...
NEO| Name | Value |
|---|---|
| Revenues | 138.7M |
| Cost of Revenue | 81.9M |
| Gross Profit | 56.8M |
| Operating Expense | 81.7M |
| Operating I/L | -24.8M |
| Other Income/Expense | -0.7M |
| Interest Income | 0.9M |
| Pretax | -25.5M |
| Income Tax Expense | -2.8M |
| Net Income/Loss | -22.7M |
NeoGenomics, Inc. operates cancer-focused testing laboratories globally, offering cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and molecular testing services to hospitals, labs, oncologists, and pharmaceutical firms. Its services include morphologic analysis and support for pharmaceutical oncology programs. The company generates revenue by providing comprehensive testing solutions for the diagnosis and treatment of cancer, as well as supporting pharmaceutical clients' oncology programs from discovery to commercialization.
